Dichlorphenamide



- TRADE NAMES: Daranide; Keveyis (Taro)
- INDICATIONS: Glaucoma (Daranide), primary hyperkalemic or hypokalemic periodic paralysis (Keveyis)
- CLASS: Carbonic anhydrase inhibitor
- HALF-LIFE: 8 minutes
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aspirin, Cyclosporine, Diflunisal, Lithium, Metformin, Primidone, Salicylates, Salsalate
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations 
- Breast feeding
- Geriatric
- Pediatric